It has been shown that only a small number of CD4+ effector T cells (about 1% of tumor-infiltrating immune cells) are located at the tumor invasion edge, where they interact with CD11c+MHC-II+ antigen-presenting immune cells and indirectly eliminate tumors. Here, ITGAX is linked to neoplasm.